A Phase 1b Multicenter Pre-Surgical Study to Evaluate Immune Biomarker Modulation in Response to Motolimod (VTX-2337) in Combination With Nivolumab in Subjects With Resectable Squamous Cell Carcinoma of the Head and Neck (SCCHN)
试验速览
- 阶段
- 1 期
- 状态
- 终止
- 发起方
- Celgene
- 入组人数
- 15
- 试验地点
- 12
- 主要终点
- Numbers of CD8+ T cells within the tumor pre-treatment and post-surgery
研究概览
简要总结
This is an open label, Phase 1b pre-operative window of opportunity biomarker trial to analyze the combination of intravenous (IV) anti-PD-1 inhibitor, nivolumab, given along with toll-like receptor 8 (TLR 8) agonist motolimod delivered either subcutaneously (SC) or by intratumoral injection (IT) in subjects with squamous cell carcinoma of the head and neck (SCCHN). Subjects with previously untreated, resectable SCCHN, will be recruited onto this trial and will initially undergo pre-treatment diagnostic imaging and biological sample collection. These subjects will undergo pre-operative study treatment for a 3 to 4-week period prior to a scheduled surgical resection.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subject is ≥ 18 years of age at the time of signing the informed consent form (ICF).
- •Subject has Eastern Cooperative Oncology Group (ECOG) PS of 0 or
- •Subject has a new clinical or pathologic diagnosis of resectable HPV+ or HPV- SCCHN of the oral cavity, pharynx, or larynx
- •Macroscopic complete resection of the primary tumor must be planned and subjects should have no medical contraindication to surgery.
- •Subject consents to and has tumor accessible for tumor biopsy pre-treatment.
- •Subjects must have acceptable hematopoietic, liver, renal, and coagulation function as assessed by laboratory tests.
排除标准
- •Subject has any significant medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from participating in the study
- •Subject has unresectable or inoperable tumors
- •Subject has primary tumors of the sinuses, paranasal sinuses, or nasopharynx, or unknown primary tumors
- •Subject has evidence of distant metastasis
- •Subject is a pregnant or nursing female.
- •Subject has active or uncontrolled infection including known HIV infection or known chronic hepatitis B or C.
- •Subject has active autoimmune disease.
- •Subject has clinically significant ophthalmologic disease.
研究组 & 干预措施
Monotherapy Arm 2: Motolimod
Motolimod IT injection weekly
干预措施: VTX-2337 (Drug)
Combination Arm 3: Nivolumab and Motolimod
Nivolumab IV every 2 weeks and Motolimod IT injection weekly
干预措施: VTX-2337 (Drug)
Combination Arm 4: Nivolumab and Motolimod
Nivolumab IV every 2 weeks and Motolimod SC injection weekly
干预措施: VTX-2337 (Drug)
Monotherapy Arm 1: Nivolumab
Nivolumab IV every 2 weeks
干预措施: Nivolumab (Drug)
Combination Arm 3: Nivolumab and Motolimod
Nivolumab IV every 2 weeks and Motolimod IT injection weekly
干预措施: Nivolumab (Drug)
Combination Arm 4: Nivolumab and Motolimod
Nivolumab IV every 2 weeks and Motolimod SC injection weekly
干预措施: Nivolumab (Drug)
结局指标
主要结局
Numbers of CD8+ T cells within the tumor pre-treatment and post-surgery
时间窗: Screening through Study Day 52
Tumor immune modulation will be evaluated by counting the number of tumor infiltration CD8+ T cells before and after treatment.
次要结局
- Number of Patients With adverse events that lead to delay in resection(Screening through Study Day 52)
- Evaluation of safety and tolerability of nivolumab, motolimod and the combination of nivolumab with motolimod(Up to approximately 112 days)